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OBJECTIVE: To evaluate whether germline variants of the succinate dehydrogenase genes might be phenotypic
modifiers in patients with multiple endocrine neoplasia type 2. Mutations of genes encoding subunits of the
succinate dehydrogenase are associated with hereditary paraganglioma/pheochromocytoma syndrome.
Pheochromocytoma is one of the main manifestations of multiple endocrine neoplasia type 2 caused by germline
mutation of the rearranged during transfection proto-oncogene.
METHODS: Polymorphisms of the succinate dehydrogenase genes were analyzed in 77 rearranged during
transfection mutation carriers, 47 patients with sporadic medullary thyroid cancer, 48 patients with sporadic Pheo,
and 100 healthy individuals. Exons 10–16 of the rearranged during transfection proto-oncogene were analyzed by
direct DNA sequencing, and all exons of the von Hippel-Lindau, succinate dehydrogenase B, and succinate
dehydrogenase subunit D genes were tested by direct DNA sequencing and multiple ligation probe analysis. The
G12S polymorphism of the succinate dehydrogenase subunit D gene was determined by restriction fragment length
polymorphism.
RESULTS: Of the 77 rearranged during transfection mutation carriers, 55 from 16 families had multiple endocrine
neoplasia type 2A, three from three families had multiple endocrine neoplasia type 2B, and 19 from two families
had familial medullary thyroid carcinoma. Eight of 55 (14.5%) patients with multiple endocrine neoplasia type 2A
had this variant whereas it was absent in multiple endocrine neoplasia type 2B, familial medullary thyroid
carcinoma, sporadic medullary thyroid carcinoma, and sporadic pheochromocytoma groups, and its prevalence in
controls was 1% (p,0.002 multiple endocrine neoplasia type 2A versus controls). No associations between G12S and
age of manifestation, incidence of pheochromocytoma or hyperparathyroidism, or level of serum calcitonin were
observed.
CONCLUSION: The high prevalence of the G12S variant in patients with multiple endocrine neoplasia type 2A raises
questions about its role as a genetic modifier, but this proposal remains to be established.
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INTRODUCTION
The RET (rearranged during transfection) proto-oncogene
located on chromosomal region 10q11.2 consists of 21 exons,
and it encodes a receptor tyrosine kinase (1). Germline gain-
of-function mutations of the RET proto-oncogene cause
multiple endocrine neoplasia type 2 (MEN2), an autosomal
dominantly inherited disease with an approximate preva-
lence of 2.5 per 100.000 in the general population (1). MEN2
has three subtypes: i) MEN2A, characterized by medullary
thyroid carcinoma (MTC), pheochromocytoma (Pheo) and
primary hyperparathyroidism; ii) MEN2B, which presents
with the most aggressive MTC, pheochromocytoma, neuro-
mas and marfanoid phenotype; and iii) familial MTC
(FMTC), the mildest form of MTC. Several important
genotype–phenotype associations have been determined;
the most commonly affected codon, 634 (nearly 85% of
MEN2A cases), frequently associates with Pheo and
hyperparathyroidism, whereas mutations of codons 609,
611, 618, and 620 (accounting for 10–15% of MEN2A)
usually associate with the milder form of MEN2 (1–3).
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85However, the phenotypic heterogeneity observed even in
members of the same family suggests that other factors, for
example genetic modifiers, may influence the clinical
manifestation of the disease (4–7).
Hereditary paraganglioma/pheochromocytoma (PGL)
syndrome is caused by the germline heterozygous muta-
tions of the SDHx genes (SDHB, SDHC, SDHD, encoding
subunits B, C and D, respectively) (8–10) and the newly
identified SDH5 gene (11) and TMEM127. SDHx genes
encode subunits of the mitochondrial complex II (succinate
dehydrogenase, SDH), an enzyme involved in oxidative
phosphorylation and intracellular oxygen sensing and
signaling (12).
Both MTC and paraganglioma/pheochromocytoma arise
from neural crest-derived precursor cells. Accumulation of
amino-acid coding polymorphisms (S163P in SDHB, G12S,
and H50R in SDHD) has been found among patients with
MTC, especially in those with familial tumors (13). In
addition, these rare genetic variants have been identified in
patients with Cowden-like syndrome (14) and the H50R
polymorphism has been described in six members of
a family with non-RET-associated C-cell hyperplasia
and hypercalcitoninemia (15). These previous data may
suggest a possible connection between SDHx polymorph-
isms and familial MTC and/or C-cell hyperplasia/hyper-
calcitoninemia; however, the occurrence of the SDHx
variants among patients harboring germline RET muta-
tions has not been previously examined. Therefore, the aim
of the present study was to investigate whether poly-
morphisms of the SDHx genes could influence clinical
manifestations of the disease in a cohort of subjects
harboring RET mutations. In addition, we wanted to
determine whether the prevalence of SDHx polymorph-
isms in patients with sporadic MTC, sporadic Pheo and
healthy subjects might be different from that found in RET
mutation carriers.
PATIENTS AND METHODS
Written informed consent was obtained from all patients
and family members who participated in the study. Patients
underwent a complete clinical examination, laboratory
testing, including serum basal calcitonin measurement
[hCalcitonin IRMA kit (Diagnostic Systems Laboratories,
Inc., Budapest, Hungary), reference range: male ,15 pg/ml,
female ,10 pg/ml until December 2007; and Liaison
(Diasorin SPA, Stillwater, MN, USA), reference value: male
,18.9 pg/ml and female ,6 pg/ml after January 2008],
plasma parathyroid hormone (Elecsys; Roche Diagnostics,
Basel, Switzerland), urinary catecholamine metabolites
(high pressure liquid chromatography with electrochemical
detection), and imaging studies, including cervical ultra-
sonography, thoracal and abdominal computed tomogra-
phy (CT), and whole-body metaiodobenzylguanidine
scintigraphy (MIBG).
Patients with MEN2 syndrome
In total, 77 patients with germline RET proto-oncogene
mutations who were members of 21 unrelated families with
MEN2 syndrome were identified by genetic screening at our
center. Of the 77 patients, 55 had MEN2A (mean age at
diagnosis: 33.4¡17 years; range: 7–76 years), three had
MEN2B (mean age at diagnosis: 15.6¡5 years; range: 10–20
years), and 19 had FMTC (mean age at diagnosis: 23.7¡16.8
years; range: 2–57 years). The presence of Pheo and MTC
were confirmed by histologic examination of surgically
removed tumors. Total thyroidectomy was performed in all
patients with germline RET mutation in the symptomatic
group and was also offered to all individuals from the
asymptomatic group.
Patients with sporadic MTC
The study included 47 unrelated patients with histologi-
cally confirmed MTC evaluated consecutively at the 2nd
Department of Medicine, Faculty of Medicine, Semmelweis
University between 1998 and 2010. There were 15 men (age,
mean ¡ SD, 44.7¡13.3; range: 28–82 years) and 32 women
(age, mean ¡ SD, 47.7¡12,3; range: 23–76 years). Pre-
operative evaluation included medical history, physical
examination, thyroid and abdominal ultrasonography, CT
or magnetic resonance imaging (MRI), MIBG-scintigraphy,
routine biochemical testing, serum calcitonin measure-
ments, and mutation analysis of exons 10–14 of the RET
gene.
Patients with apparently sporadic Pheo
The study included 48 unrelated patients with histo-
logically confirmed sporadic adrenal pheochromocyto-
mas evaluated consecutively at the 2nd Department of
Medicine, Faculty of Medicine, Semmelweis University
between 1998 and 2010. There were 16 men (age, mean ¡
SD, 36¡14; range: 13–66 years) and 32 women (age, mean
¡ S.D, 42¡14; range: 19–64 years). Pre-operative evalua-
tion included medical history, physical examination,
abdominal ultrasonography, CT or MRI, MIBG-scintigra-
phy, routine biochemical testing, and 24 h urinary catecho-
lamine metabolite determination. The mutation analysis of
RET exons 10–14 and the entire VHL, SDHB, and SDHD
genes revealed no disease-causing mutations. Patients with
confirmed VHL (five patients), SDHB (one patient), or
SDHD (one patient) mutations were excluded from the
study. Five patients were initially thought to have sporadic
pheochromocytoma, but were later identified as having a
disease-causing RET mutation and were included in the
study as RET mutation carriers. MTC, either by elevated
serum calcitonin or by postoperative histology, had been
diagnosed in all of these patients. Genetic counseling and
genetic screening for all first-degree relatives have been
offered.
Germline mutation screening of the RET, VHL,
SDHB, and SDHD genes
Genomic DNA was isolated from peripheral blood using
the Roche DNA Isolation Kit (Roche Diagnostics GmbH,
Mannheim, Germany) and QIAamp DNA Blood Mini Kit
(Qiagen Inc., Valencia, CA, USA) in accordance with the
manufacturers’ instructions. RET proto-oncogene muta-
tions were detected by direct sequencing as previously
reported (16,17). Mutation analysis of the VHL, SDHB, and
SDHD genes in cases of apparently sporadic Pheo were
performed by direct sequencing of the entire coding region
of the VHL, SDHB, and SDHD genes, as previously
reported (17,18), and large deletion analysis of the VHL,
SDHB, SDHC, and SDHD genes performed using multiplex
ligation probe amplification (18).
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analysis for identification the G12S polymorphism
of the SDHD gene
The nucleotide change of G to A, which corresponds to
the G12S polymorphism, results in the preservation of the
BanI restriction cleavage site. Therefore, digestion with the
BanI restriction enzyme (New England BioLabs Inc.,
Ipswich, MA, USA) for 90 min at 37˚C was performed after
polymerase chain reaction (PCR) amplification of exon 1 of
the SDHD gene for genotyping of RET mutation carriers,
sporadic MTC patients, and 100 controls (Figure 1). Samples
from patients with positive results were examined by direct
DNA sequencing. The results obtained with both methods
were the same in all cases.
Statistical analysis
Baseline characteristics were compared using the chi-
squared test or Fisher’s exact test for qualitative variables,
and Student’s t test or Mann-Whitney’s U test for
quantitative variables. The statistical package SPSS 15.0
(SPSS Inc., Chicago, IL, USA) was used and p,0.05 was
considered statistically significant.
RESULTS AND DISCUSSION
Eight of the 55 patients with MEN2A (15.5%) had the G12S
variant, whereas it was absent in the MEN2B and FMTC
groups. No patient withsporadicMTC and/or sporadicPheo
carried this variant. Among the 100 population-based,
healthy control individuals, only one individual carried this
variant (prevalence, 1%) (Table 1). No association between
the G12S polymorphism of the SDHD gene and the incidence
of Pheo or hyperparathyroidism in RET mutation carriers
was observed, and the age of disease manifestation was
similar in G12S carriers and in non-carriers (43¡9 versus
40¡3 years in probands and 29.6¡19.3 versus 32.5¡20.5
years in non-carriers). Among probands with RET mutations,
carriers of the G12S had higher serum calcitonin levels
compared with those who did not carry the SDHD G12S
variant (6,864¡11,111 versus 1,250¡932 pg/ml), but the
difference was not significant. Among family members with
RET mutations, serum calcitonin levels were similar in G12S
carriers and non-carriers 436¡876 versus 393¡556 pg/ml)
(Table 2).
The phenotypic heterogeneity seen in families with
different RET mutations, the variation of clinical course
within families with the same RET mutation, and the results
from RET transgenic mouse models suggest a potential role
of genetic components in phenotype modulation (2,19).
Polymorphisms of the RET gene have been analyzed as such
genetic modifiers, but the results from these studies are
conflicting. Robledo et al. showed that two RET variants
(G691S and S904S) may modify the age of onset of MTC in
family members (5); and Tamanaha et al. reported that two
intronic polymorphisms of RET may modify the phenotype
in a large family with G533C RET mutation (7), while
Baumgartner-Parzer found that the L769L and the IVS14-24
may act as modifiers in some forms of hereditary and
sporadic MTC (20). However, Lesueur et al. were unable to
replicate this association in a large cohort of 384 members of
MEN2 families from four different European populations.
This latter study showed that of the several polymorphisms
of genes encoding the RET protein, its co-receptors and
ligands, only the synonymous polymorphism A432A of the
RET gene associated weakly with tumor spectra in patients
with MEN2A (6). MEN2-related MTC RET variants have
been analyzed as genetic susceptibility factors for the
development of sporadic MTC: polymorphisms located in
coding regions of RET, G691S, L769L, S836S, and S904S have
been shown to be over-represented in patients with sporadic
Figure 1 - (A) Gel electrophoresis of PCR fragments after digestion with BanI for identification of the G12S polymorphism of the SDHD
gene by RFLP (L = DNA ladder; C+ = positive control; heterozygote for G12S; C- = negative control; G12 normal, P1–P5 = patients. (B)
Chromatograms of exon 1 of the SDHD gene showing the wild type and the heterozygote form of the G12S (GGT12AGT)
polymorphism.
Table 1 - Prevalence of the G12S polymorphism of the SDHD gene among germline RET mutation carriers, patients with
sporadic medullary thyroid cancer, patients with sporadic pheochromocytomas, and healthy controls.
MEN2A FMTC MEN2B Spoaradic MTC Spoaradic Pheo Control
8/55 (15.5%)* 0/19 (0%) 0/3 (0%) 0/47 0/48 1/100 (1%)
*p,0.002 versus control group.
FMTC = familiar medullary thyroid cancer; MEN2A = multiple endocrine neoplasia type 2A; MEN2B = multiple endocrine neoplasia type 2B; MTC =
medullary thyroid cancer; Pheo = pheochromocytoma.
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others were unable to confirm these associations (24,25).
Germline mutations of SDHx genes encoding subunits of
the mitochondrial complex II represent a genetic suscept-
ibility for Pheo/PGL. These tumors are derived from cells of
the neural crest, similar to MTC. RET mutations also cause
Pheo, again suggesting a link between the genetic back-
ground of Pheo and MTC. Therefore, it has been assumed
that mutations of these genes may be involved in the
pathogenesis of MTC. Lima et al. reported a family with C-
cell hyperplasia, a pre-cancerous state of MTC, who were
proved to have the H50R variant of the SDHD gene (15).
Montani et al. demonstrated an increased frequency of
amino acid-coding SDHx polymorphisms in patients with
sporadic and familial MTC (13). In addition, a systemic
evaluation of genetic variants of the SDHx genes among
patients with sporadic MTC showed a significant associa-
tion between the H50R variant and sporadic MTC in
Spanish patients, although this observation was absent in
an English cohort (26). Variants of the SDHx genes have
been implicated in the pathogenesis of various endocrine
and non-endocrine tumors, such as Merkel cell carcinoma,
carcinoid, papillary thyroid cancer, and renal cell cancer
found in patients with Cowden-like syndrome (14).
In the present study, we found that the G12S variant was
significantly over-represented among RET mutation carriers
compared with sporadic MTC, sporadic Pheo, or control
individuals. In our study, this variant occurred mainly in
patients with MEN2A, while Montani et al. detected G12S in
a patient with MEN2B harboring the M918T mutation of the
RET gene (13). Interestingly, the prevalence of alterations of
the SDHx genes in patients with RET mutations was similar
in our study and the study of Montani et al. (13).
The prevalence of the G12S in the general population is
between 2.5% and 5% (27) according to the Leiden Open
Variation Database (http://chromium.liacs.nl) (28), which
is somewhat higher than in our control population (1%).
This difference may be due to differences in the selection
criteria applied for controls. Our control group were
evaluated for endocrine dysfunction; none of them had
signs or symptoms characteristic of thyroid cancer or Pheo.
By contrast, population-based controls, frequently anon-
ymous blood donors, have never been tested for these rare
conditions. Alternatively, the difference between the
studies in prevalence of G12S can also be attributed to
the ethnic background of the different populations tested.
Our patients and controls were of Hungarian origin,
representing an independent entity among Caucasian
populations. More importantly, in our study, the high
incidence of the G12S variant among RET carriers,
especially in those with the MEN2A phenotype, raised
the possibility that this variant may have a role in the
phenotypic modulation of the disease. However, we were
unable to detect significant differences in the clinical
presentation between G12S carriers and non-carriers.
Whether this failure was a result of the relatively small
size of our patient cohorts remains to be further investi-
gated. Interestingly, Waldmann et al. reported an increased
prevalence of intronic SDHB polymorphisms among
patients with malignant Pheo compared with patients with
benign tumors (29).
In conclusion, we found a significantly higher prevalence
of the G12S variant of the SDHD gene among germline RET
mutation carriers presenting with MEN2A compared with
the control group. The high prevalence of the G12S variant
in these patients supports its genetic modifier role, but this
proposal remains to be established.
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